Trastuzumab pamirtecan versus chemotherapy in patients with previously treated, human epidermal growth factor receptor 2 (HER2)-expressing, recurrent endometrial cancer: the phase 3 Fern-EC-01 trial (BNT323-01/GOG-3105/ENGOT-EN25)

International Journal of Gynecological Cancer · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles